KYNTRA BIO director granted 7,000 stock options
KYNTRA BIO, INC. director Michael Kauffman received a grant of stock options covering 7,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
KYNTRA BIO, INC. director Michael Kauffman received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. These options vest in four equal quarterly installments from the grant date, and his reported option holdings following this grant total 7,000 derivative securities.
Insider Trade Summary
Grant/Award: 7,000 shares
Grant/Award
1 txn
Insider
Kauffman Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 7,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 7,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.
Key Figures
Options granted: 7,000 options
Exercise price: $7.13 per share
Expiration date: June 11, 2036
+2 more
5 metrics
Options granted
7,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$7.13 per share
Exercise price of stock option grant
Expiration date
June 11, 2036
Option expiration for 7,000-share grant
Post-grant derivative holdings
7,000 options
Total derivative securities following transaction
Vesting schedule
Four equal quarterly installments
Measured from the date of grant per footnote
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, derivative securities, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 7.1300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative securities financial
"derivativeTransactionCount: 1 derivative transaction"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vest in four equal quarterly installments financial
"The shares subject to the option shall vest in four equal quarterly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did KYNTRA BIO (KYNB) director Michael Kauffman report in this Form 4?
Michael Kauffman reported receiving a grant of stock options for 7,000 shares of KYNTRA BIO common stock. These options were awarded as a compensation-related acquisition, rather than an open-market purchase or sale, and are held directly in his name.
What are the key terms of Michael Kauffman’s 7,000 KYNTRA BIO stock options?
The granted stock options cover 7,000 shares of common stock at an exercise price of $7.13 per share. They expire on June 11, 2036, giving a long exercise window, and represent a right to buy shares rather than an immediate ownership transfer.
How do Michael Kauffman’s KYNTRA BIO options vest over time?
The options vest in four equal quarterly installments measured from the grant date. This means 25% of the 7,000-share grant vests each quarter, aligning continued service with the gradual ability to exercise and acquire underlying common shares.
What is Michael Kauffman’s reported KYNTRA BIO option position after this grant?
Following the grant, the filing shows Kauffman holding 7,000 derivative securities in the form of stock options. This reflects the full 7,000-share option award, with no additional remaining derivative positions listed in the derivative summary section.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates